{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T02:15:53Z","timestamp":1783131353519,"version":"3.54.6"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":3077,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Ciprofloxacin generic tablets approved for human use frequently are administered to dogs for treatment of bacterial infections because they are inexpensive and readily available. However, previous work indicated low and variable oral absorption in healthy research dogs.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To examine orally administered ciprofloxacin in a group of clinical canine patients using population pharmacokinetics in order to identify minimum inhibitory concentrations (MIC) that potentially could be achieved with orally administered ciprofloxacin in dogs.<\/jats:p>\n <\/jats:sec>\n \n Animals<\/jats:title>\n Thirty-four clinical canine patients; mean weight, 22.95\u00a0kg (range, 4.6\u201357\u00a0kg).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Ciprofloxacin generic tablets intended for human use were administered to dogs in a prospective study (mean dose, 23.5\u00a0mg\/kg). Sparse blood sampling was used to obtain population pharmacokinetic results with nonlinear mixed-effects modeling. These data were used to estimate a breakpoint for susceptible bacteria. Monte Carlo simulations were used to determine the probability of target attainment (PTA) for an area under the curve (AUC)\/MIC ratio of \u2265100, the pharmacokinetic-pharmacodynamic target for fluoroquinolones.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The values for volume of distribution, peak concentration, and half-life were 10.7\u00a0L\/kg (11.7%), 1.9\u00a0\u03bcg\/mL (11.66%), and 4.35\u00a0hours (7.62%), respectively (mean, % coefficient of variation [CV]). The size of the dog was an important covariate with larger dogs achieving lower plasma drug concentrations than smaller dogs, despite a similar mg\/kg dose. Ninety percent PTA was obtained for a MIC\u00a0\u2264\u00a00.06\u00a0\u03bcg\/mL.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Clinical Importance<\/jats:title>\n A breakpoint (susceptible) of \u22640.06\u00a0\u03bcg\/mL should be considered when ciprofloxacin tablets are administered to dogs at a dose of 25\u00a0mg\/kg once daily, which is much lower than the breakpoint of \u22641\u00a0\u03bcg\/mL in humans.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jvim.14788","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T16:11:09Z","timestamp":1501776669000},"page":"1508-1513","source":"Crossref","is-referenced-by-count":28,"title":["Ciprofloxacin Pharmacokinetics in Clinical Canine Patients"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-7898","authenticated-orcid":false,"given":"M.G.","family":"Papich","sequence":"first","affiliation":[{"name":"College of Veterinary Medicine, North Carolina State University , Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,9,1]]},"reference":[{"key":"2026020303214842000_jvim14788-bib-0001","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/jac\/dkq093","article-title":"Effect of generics on price and consumption of ciprofloxacin in primary healthcare: The relationship to increasing resistance","volume":"65","author":"Jensen","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2026020303214842000_jvim14788-bib-0002","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1439-0442.1995.tb00405.x","article-title":"Ciprofloxacin pharmacokinetics in dogs following oral administration","volume":"42","author":"Abad\u00eda","year":"1995","journal-title":"Zentralbl Veterinarmed A"},{"key":"2026020303214842000_jvim14788-bib-0003","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2885.1994.tb00264.x","article-title":"Disposition of ciprofloxacin following intravenous administration in dogs","volume":"17","author":"Abad\u00eda","year":"1994","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020303214842000_jvim14788-bib-0004","doi-asserted-by":"crossref","first-page":"896","DOI":"10.2460\/ajvr.1990.51.06.896","article-title":"Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs","volume":"51","author":"Walker","year":"1990","journal-title":"Am J Vet Res"},{"key":"2026020303214842000_jvim14788-bib-0005","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1128\/AAC.34.1.89","article-title":"Pharmacokinetics of a novel quinolone, AT-4140, in animals","volume":"34","author":"Nakamura","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020303214842000_jvim14788-bib-0006","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2460\/ajvr.73.7.1085","article-title":"Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs","volume":"73","author":"Papich","year":"2012","journal-title":"Am J Vet Res"},{"key":"2026020303214842000_jvim14788-bib-0007","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF01117450","article-title":"Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations","volume":"6","author":"Yamaoka","year":"1978","journal-title":"J Pharmacokinet Biopharm"},{"key":"2026020303214842000_jvim14788-bib-0008","article-title":"Pharmacokinetics","author":"Gibaldi","year":"1982","edition":"2"},{"key":"2026020303214842000_jvim14788-bib-0009","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1086\/383320","article-title":"Relationship between fluoroquinolone area under the curve: Minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia","volume":"189","author":"Drusano","year":"2004","journal-title":"J Infect Dis"},{"key":"2026020303214842000_jvim14788-bib-0010","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/nrmicro862","article-title":"Antimicrobial pharmacodynamics: Critical interactions of\u2019 bug and drug","volume":"2","author":"Drusano","year":"2004","journal-title":"Nat Rev Microbiol"},{"issue":"5","key":"2026020303214842000_jvim14788-bib-0011","doi-asserted-by":"crossref","first-page":"2S27","DOI":"10.1111\/j.1469-0691.1998.tb00692.x","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"4","author":"Drusano","year":"1998","journal-title":"Clin Microbiol Infect"},{"key":"2026020303214842000_jvim14788-bib-0012","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2885.2005.00664.x","article-title":"Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs","volume":"28","author":"Bidgood","year":"2005","journal-title":"J Vet Pharmacol Ther"},{"key":"2026020303214842000_jvim14788-bib-0013","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1128\/CMR.00047-06","article-title":"Setting and revising antibacterial susceptibility breakpoints","volume":"20","author":"Turnidge","year":"2007","journal-title":"Clin Microbiol Rev"},{"key":"2026020303214842000_jvim14788-bib-0014","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jvim.13796","article-title":"Effect of sucralfate on the relative bioavailability of enrofloxacin and ciprofloxacin in healthy fed dogs","volume":"30","author":"KuKanich","year":"2016","journal-title":"J Vet Intern Med"},{"key":"2026020303214842000_jvim14788-bib-0015","article-title":"CLSI Supplement M100S","author":"CLSI","year":"2016","edition":"26"},{"key":"2026020303214842000_jvim14788-bib-0016","article-title":"CLSI Document VET01-S3","author":"Clinical Laboratory Standards Institute, CLSI","year":"2015"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.14788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/31\/5\/1508\/66672230\/jvim14788.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/31\/5\/1508\/66672230\/jvim14788.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:21:55Z","timestamp":1770106915000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/31\/5\/1508\/8449307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,1]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.14788","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,9]]},"published":{"date-parts":[[2017,9,1]]}}}